Identity
What is Tesamorelin?
A synthetic GHRH(1-44) analog with an N-terminal trans-3-hexenoyl group (development code TH9507).

Research reference · Hormones
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone and the active ingredient in FDA-approved Egrifta, used for excess abdominal fat in people with HIV.
Published by Elevated Pharma ·
Identity
A synthetic GHRH(1-44) analog with an N-terminal trans-3-hexenoyl group (development code TH9507).
Research context
Randomized trials in people with HIV cover visceral fat, fatty liver and neurocognition; smaller studies examine people without HIV.
Evidence boundary
Approval of a prescription product does not transfer to an unlabeled research material.
U.S. status · November 7, 2026
FDA-approved as Egrifta SV and Egrifta WR for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Prescribing information is the controlling source.
Key studies
Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.
Search all 95 PubMed records for Tesamorelin · Counts and selections checked November 7, 2026.
Reference identifiers
Database identity describes the reference substance, not any specific material or lot.
Official & primary sources
Citation does not imply an Elevated Pharma partnership or endorsement.